Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517790 · ClinicalTrials.gov registry record · Phase 2
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00517790 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 140 participants.
The verdict
NCT00517790, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.
Interventions
- DRUG ABT-869 .25 mg/kg
- DRUG ABT-869 0.10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517790
The ClinicalTrials.gov registry entry for NCT00517790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-869 .25 mg/kg is the first listed.
NCT00517790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517790 about?
NCT00517790 is a clinical study titled "Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.
What is the current status of trial NCT00517790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2007-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00517790?
The interventions under investigation include: ABT-869 .25 mg/kg (DRUG), ABT-869 0.10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00517790?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.